Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Primes Late-Stage Psoriasis Asset With Samsung Manufacturing Deal

Executive Summary

Sun Pharma has firmed up a manufacturing pact for tildrakizumab with Samsung BioLogics, securing supplies of its late-stage psoriasis asset in an increasingly competitive segment. The deal also underscores Samsung’s expanding stature as a frontline CMO in the biologics space.

You may also be interested in...



Indo-Korean Pharma Linkages: A New Emerging Asian Front?

Is there a new strategic Asian pharma partnership in the works? Early days perhaps but worth keeping an eye on the India-South Korea deal street.

Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended

The latest drug development news and highlights from our US FDA Performance Tracker.

Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset

Sun Pharma reported a sharp decline in Q3 profits, dented by tax adjustments related to changes in US tax rates and continuing pricing pressures there. With Q4 revenues expected to to be "similar” to Q3, all eyes are on the Halol site making the compliance cut and the upcoming PDUFA date for Sun’s psoriasis asset.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel